Mayo Clinic Announces Collaboration with InNexus

Monday, September 12, 2005

SCOTTSDALE, Ariz. — Mayo Clinic announced an agreement to collaborate with InNexus Biotechnology, Inc. of Vancouver, British Columbia. Last May, an agreement to collaborate on development of disease fighting antibodies was reached and now InNexus will be the second company to locate to the new Mayo Clinic Collaborative Research Building (MCCRB) on the Scottsdale Campus. Currently in the building is The Center for Translational Drug Development (TD2) a subsidiary of Translational Genomics Research Institute (TGen).

To bring new technology and treatments to our patients, Mayo Clinic and InNexus will be working together on the development of new antibody therapies in the areas of cancer and immune dysfunction diseases. The objective of the collaboration between Mayo Clinic and InNexus is to create synergy through the combined strength of InNexus' antibody development platform and Mayo Clinic's clinical research.

Mayo Clinic is expanding their collaborative network through biotechnogy. In June, the 110,000-square-foot Mayo Clinic Collaborative Research Building (MCCRB) opened on Mayo's Scottsdale campus. The MCCRB is the first of its kind for Mayo Clinic in that it brings multiple strategic partners under one roof, working on scientific discoveries that will help patients. The new building expands upon state-of-the-art research activities being conducted by Mayo investigators in the nearby Samuel C. Johnson Research Building.

Mayo Clinic Cancer Center is one of only 39 U.S. medical centers that have been named as a National Cancer Institute (NCI) Comprehensive Cancer Center. To receive this designation, an institution must meet rigorous standards demonstrating clinical excellence in treating cancer patients and scientific excellence in its research programs. Mayo Clinic Cancer Center is ranked by the NCI as one of the top 10 cancer centers in the nation, and is the only national, multi-site center with the NCI's Comprehensive Cancer Center designation. In Arizona, Mayo's clinical and research experts work together to address the complex needs of cancer patients, with a dedication to understanding the biology of cancer; discovering new ways to predict, prevent, diagnose and treat cancer; and transforming the quality of life for cancer patients today and in the future.

###

To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com is available as a resource for your health stories.